Document is current

Article History

Received: 6 July 2019

Accepted: 5 October 2019

First Online: 4 December 2019

Ethics approval and consent to participate

: The welfare of the mice was maintained in accordance with the general principles governing the use of animals in experiments of the European Communities (Directive 2010/63/EU) and Dutch legislation (The revised Experiments on Animals Act, 2014). This included licensing of the project by the Central Committee on Animal Experimentation (project license 3721) and approval of the study by the Triskelion Animal Welfare Body (AWB number TRIS-200).The NHP study was performed in compliance with the German Animal Welfare Act and was approved by the local IACUC (applied for by Covance Preclinical Services GmbH). This study was performed in consideration of the DIRECTIVE 2010/63/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22 September 2010 on the protection of animals used for scientific purposes. In addition, this study was performed in consideration of the Commission Recommendation 2007/526/EC on guidelines for the accommodation and care of animals used for experimental and other scientific purposes (Appendix A of Convention ETS 123).

: Not applicable.

: The authors have been or are employees of Aduro Biotech, Inc. and have stocks and/or stock options in Aduro Biotech, Inc. The authors do not have any financial competing interests. EV, PV, DLH, AvE and HvE have filed a patent application (WO2018/190719) that describes the invention of the anti-SIRPα antibody hSIRPα.40A and its humanized variant ADU-1805. All the company-employed authors declare that their employment does not alter their adherence to the policies of Journal for Immunotherapy of Cancer.